MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact
MicroRNAs are well-known strong RNA regulators modulating whole functional units in complex signaling networks. Regarding clinical application, they have potential as biomarkers for prognosis, diagnosis, and therapy. In this review, we focus on two microRNAs centrally involved in lung cancer progres...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-07-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317706430 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849249150332305408 |
|---|---|
| author | Meik Kunz Claudia Göttlich Thorsten Walles Sarah Nietzer Gudrun Dandekar Thomas Dandekar |
| author_facet | Meik Kunz Claudia Göttlich Thorsten Walles Sarah Nietzer Gudrun Dandekar Thomas Dandekar |
| author_sort | Meik Kunz |
| collection | DOAJ |
| description | MicroRNAs are well-known strong RNA regulators modulating whole functional units in complex signaling networks. Regarding clinical application, they have potential as biomarkers for prognosis, diagnosis, and therapy. In this review, we focus on two microRNAs centrally involved in lung cancer progression. MicroRNA-21 promotes and microRNA-34 inhibits cancer progression. We elucidate here involved pathways and imbed these antagonistic microRNAs in a network of interactions, stressing their cancer microRNA biology, followed by experimental and bioinformatics analysis of such microRNAs and their targets. This background is then illuminated from a clinical perspective on microRNA-21 and microRNA-34 as general examples for the complex microRNA biology in lung cancer and its diagnostic value. Moreover, we discuss the immense potential that microRNAs such as microRNA-21 and microRNA-34 imply by their broad regulatory effects. These should be explored for novel therapeutic strategies in the clinic. |
| format | Article |
| id | doaj-art-c0b682f0595040adb0a80f7a367c421a |
| institution | Kabale University |
| issn | 1423-0380 |
| language | English |
| publishDate | 2017-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-c0b682f0595040adb0a80f7a367c421a2025-08-20T03:57:39ZengSAGE PublishingTumor Biology1423-03802017-07-013910.1177/1010428317706430MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impactMeik Kunz0Claudia Göttlich1Thorsten Walles2Sarah Nietzer3Gudrun Dandekar4Thomas Dandekar5Functional Genomics and Systems Biology Group, Department of Bioinformatics, Biocenter, Würzburg, GermanyDepartment of Tissue Engineering and Regenerative Medicine (TERM), University Hospital Würzburg, Würzburg, GermanyDepartment of Cardiothoracic Surgery, University Hospital Magdeburg, Magdeburg, GermanyDepartment of Tissue Engineering and Regenerative Medicine (TERM), University Hospital Würzburg, Würzburg, GermanyTranslational Center Würzburg “Regenerative Therapies in Oncology and Musculoskeletal Disease”, Branch of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), Würzburg, GermanyFunctional Genomics and Systems Biology Group, Department of Bioinformatics, Biocenter, Würzburg, GermanyMicroRNAs are well-known strong RNA regulators modulating whole functional units in complex signaling networks. Regarding clinical application, they have potential as biomarkers for prognosis, diagnosis, and therapy. In this review, we focus on two microRNAs centrally involved in lung cancer progression. MicroRNA-21 promotes and microRNA-34 inhibits cancer progression. We elucidate here involved pathways and imbed these antagonistic microRNAs in a network of interactions, stressing their cancer microRNA biology, followed by experimental and bioinformatics analysis of such microRNAs and their targets. This background is then illuminated from a clinical perspective on microRNA-21 and microRNA-34 as general examples for the complex microRNA biology in lung cancer and its diagnostic value. Moreover, we discuss the immense potential that microRNAs such as microRNA-21 and microRNA-34 imply by their broad regulatory effects. These should be explored for novel therapeutic strategies in the clinic.https://doi.org/10.1177/1010428317706430 |
| spellingShingle | Meik Kunz Claudia Göttlich Thorsten Walles Sarah Nietzer Gudrun Dandekar Thomas Dandekar MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact Tumor Biology |
| title | MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact |
| title_full | MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact |
| title_fullStr | MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact |
| title_full_unstemmed | MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact |
| title_short | MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact |
| title_sort | microrna 21 versus microrna 34 lung cancer promoting and inhibitory micrornas analysed in silico and in vitro and their clinical impact |
| url | https://doi.org/10.1177/1010428317706430 |
| work_keys_str_mv | AT meikkunz microrna21versusmicrorna34lungcancerpromotingandinhibitorymicrornasanalysedinsilicoandinvitroandtheirclinicalimpact AT claudiagottlich microrna21versusmicrorna34lungcancerpromotingandinhibitorymicrornasanalysedinsilicoandinvitroandtheirclinicalimpact AT thorstenwalles microrna21versusmicrorna34lungcancerpromotingandinhibitorymicrornasanalysedinsilicoandinvitroandtheirclinicalimpact AT sarahnietzer microrna21versusmicrorna34lungcancerpromotingandinhibitorymicrornasanalysedinsilicoandinvitroandtheirclinicalimpact AT gudrundandekar microrna21versusmicrorna34lungcancerpromotingandinhibitorymicrornasanalysedinsilicoandinvitroandtheirclinicalimpact AT thomasdandekar microrna21versusmicrorna34lungcancerpromotingandinhibitorymicrornasanalysedinsilicoandinvitroandtheirclinicalimpact |